{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:26:38Z","timestamp":1794961598031,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Meta-analysis may increase the risk of random errors. Trial sequential analysis (TSA) has been developed to adjust for these random errors. We conducted TSA on the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in left ventricular thrombus (LVT) patients in order to estimate how many additional patients should be required to draw definite conclusions. PubMed, Scopus, and Cochrane Library databases were searched for articles directly comparing DOACs and VKAs for LVT in LV <jats:italic>thrombus resolution<\/jats:italic>, <jats:italic>stroke<\/jats:italic>, <jats:italic>any thromboembolism<\/jats:italic>, <jats:italic>major bleeding<\/jats:italic>, <jats:italic>any bleeding<\/jats:italic>, and <jats:italic>all-cause death<\/jats:italic>. TSA was conducted with a cumulative Z-curve, monitoring boundaries, and required sample size. A simulated trial was run and TSA estimated the sample sizes of trials needed to draw definite conclusions. Of 4749 articles, 25 studies were used for the analysis. TSA revealed the current sample size already demonstrated superiority of DOACs in LV <jats:italic>thrombus resolution<\/jats:italic> and <jats:italic>stroke,<\/jats:italic> and futility in <jats:italic>any thromboembolism<\/jats:italic> and <jats:italic>all-cause death<\/jats:italic>. Two other outcomes did not achieve the required sample size. The sample size of new trials needed to demonstrate the superiority of DOACs over VKAs was estimated 400 for <jats:italic>any bleeding<\/jats:italic>. Corresponding trials needed to demonstrate no significant differences could be estimated for <jats:italic>major bleeding<\/jats:italic> and <jats:italic>any bleeding<\/jats:italic> (n\u2009=\u2009200 and n\u2009=\u20092000, respectively). Current results show that the sample size required to draw definite conclusions was not reached for two outcomes, and there was a risk of random error. Further randomized controlled trials with sample sizes estimated by TSA will work effectively to obtain valid conclusions.<\/jats:p>","DOI":"10.1038\/s41598-023-40389-x","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T12:02:22Z","timestamp":1692014542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Trial sequential analysis of efficacy and safety of direct oral anticoagulants and vitamin K antagonists against left ventricular thrombus"],"prefix":"10.1038","volume":"13","author":[{"given":"Tetsuji","family":"Kitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"40389_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","volume":"77","author":"M Abdelnabi","year":"2021","unstructured":"Abdelnabi, M. et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial). J. Am. Coll. Cardiol. 77, 1590\u20131592. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.049 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"40389_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ehjcvp\/pvab057","volume":"8","author":"R Alcalai","year":"2022","unstructured":"Alcalai, R. et al. Apixaban vs warfarin in patients with left ventricular thrombus: A prospective multicentre randomized clinical trialdouble dagger. Eur. Heart J. Cardiovasc. Pharmacother. 8, 660\u2013667. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab057 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"40389_CR3","doi-asserted-by":"publisher","DOI":"10.4103\/jcpc.Jcpc_41_20","author":"W Isa","year":"2020","unstructured":"Isa, W. et al. Apixaban versus warfarin in patients with left ventricular thrombus: A pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus. J. Clin. Prevent. Cardiol. https:\/\/doi.org\/10.4103\/jcpc.Jcpc_41_20 (2020).","journal-title":"J. Clin. Prevent. Cardiol."},{"key":"40389_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12959-020-00242-x","volume":"18","author":"Z Ali","year":"2020","unstructured":"Ali, Z. et al. Direct oral anticoagulant use in left ventricular thrombus. Thromb. J. 18, 29. https:\/\/doi.org\/10.1186\/s12959-020-00242-x (2020).","journal-title":"Thromb. J."},{"key":"40389_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1074248420967644","volume":"26","author":"J Cochran","year":"2021","unstructured":"Cochran, J. et al. Direct oral anticoagulants in the treatment of left ventricular thrombus: A retrospective, multicenter study and meta-analysis of existing data. J. Cardiovasc. Pharmacol. Ther. 26, 173\u2013178. https:\/\/doi.org\/10.1177\/1074248420967644 (2021).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"40389_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40261-020-00898-3","volume":"40","author":"J Daher","year":"2020","unstructured":"Daher, J. et al. Management of left ventricular thrombi with direct oral anticoagulants: Retrospective comparative study with vitamin K antagonists. Clin. Drug Investig. 40, 343\u2013353. https:\/\/doi.org\/10.1007\/s40261-020-00898-3 (2020).","journal-title":"Clin. Drug Investig."},{"key":"40389_CR7","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.amjmed.2020.05.025","volume":"133","author":"R Guddeti","year":"2020","unstructured":"Guddeti, R. et al. Treatment of left ventricular thrombus with direct oral anticoagulants: A retrospective observational study. Am. J. Med. 133, 1488\u20131491. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.025 (2020).","journal-title":"Am. J. Med."},{"key":"40389_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/ehf2.12718","volume":"7","author":"H Iqbal","year":"2020","unstructured":"Iqbal, H. et al. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail. 7, 2032\u20132041. https:\/\/doi.org\/10.1002\/ehf2.12718 (2020).","journal-title":"ESC Heart Fail."},{"key":"40389_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/ehjcvp\/pvaa096","volume":"7","author":"D Jones","year":"2021","unstructured":"Jones, D. et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur. Heart J. Cardiovasc. Pharmacother. 7, 398\u2013404. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa096 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"40389_CR10","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.jacc.2019.01.032","volume":"73","author":"C McCarthy","year":"2019","unstructured":"McCarthy, C. et al. Underutilization of cardiac rehabilitation for type 2 myocardial infarction. J. Am. Coll. Cardiol. 73, 2005\u20132007. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.032 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"40389_CR11","first-page":"45","volume":"133","author":"C Ratnayake","year":"2020","unstructured":"Ratnayake, C., Liu, B., Benatar, J., Stewart, R. & Somaratne, J. Left ventricular thrombus after ST segment elevation myocardial infarction: A single-centre observational study. N. Z. Med. J. 133, 45\u201354 (2020).","journal-title":"N. Z. Med. J."},{"key":"40389_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","volume":"5","author":"A Robinson","year":"2020","unstructured":"Robinson, A. et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 5, 685\u2013692. https:\/\/doi.org\/10.1001\/jamacardio.2020.0652 (2020).","journal-title":"JAMA Cardiol."},{"key":"40389_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s43044-021-00164-7","volume":"73","author":"M Albabtain","year":"2021","unstructured":"Albabtain, M. et al. Rivaroxaban versus warfarin for the management of left ventricle thrombus. Egypt Heart J. 73, 41. https:\/\/doi.org\/10.1186\/s43044-021-00164-7 (2021).","journal-title":"Egypt Heart J."},{"key":"40389_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11239-020-02371-6","volume":"52","author":"M Bass","year":"2021","unstructured":"Bass, M. et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J. Thromb. Thrombolysis 52, 517\u2013522. https:\/\/doi.org\/10.1007\/s11239-020-02371-6 (2021).","journal-title":"J. Thromb. Thrombolysis"},{"key":"40389_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/clc.23741","volume":"44","author":"F Hofer","year":"2021","unstructured":"Hofer, F. et al. The prognostic impact of left ventricular thrombus resolution after acute coronary syndrome and risk modulation via antithrombotic treatment strategies. Clin. Cardiol. 44, 1692\u20131699. https:\/\/doi.org\/10.1002\/clc.23741 (2021).","journal-title":"Clin. Cardiol."},{"key":"40389_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/FJC.0000000000000987","volume":"77","author":"O Iskaros","year":"2021","unstructured":"Iskaros, O., Marsh, K., Papadopoulos, J., Manmadhan, A. & Ahuja, T. Evaluation of direct oral anticoagulants versus warfarin for intracardiac thromboses. J. Cardiovasc. Pharmacol. 77, 621\u2013631. https:\/\/doi.org\/10.1097\/FJC.0000000000000987 (2021).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"40389_CR17","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s11739-021-02788-8","volume":"16","author":"A Mihm","year":"2021","unstructured":"Mihm, A., Hicklin, H., Cunha, A., Nisly, S. & Davis, K. Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis. Intern. Emerg. Med. 16, 2313\u20132317. https:\/\/doi.org\/10.1007\/s11739-021-02788-8 (2021).","journal-title":"Intern. Emerg. Med."},{"key":"40389_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.11604\/pamj.2021.39.212.28585","volume":"39","author":"M Varwani","year":"2021","unstructured":"Varwani, M., Shah, J., Ngunga, M. & Jeilan, M. Treatment and outcomes in patients with left ventricular thrombus\u2014experiences from the Aga Khan University Hospital, Nairobi-Kenya. Pan. Afr. Med. J. 39, 212. https:\/\/doi.org\/10.11604\/pamj.2021.39.212.28585 (2021).","journal-title":"Pan. Afr. Med. J."},{"key":"40389_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1177\/1060028020975111","volume":"55","author":"A Willeford","year":"2021","unstructured":"Willeford, A., Zhu, W., Stevens, C. & Thomas, I. Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus. Ann. Pharmacother. 55, 839\u2013845. https:\/\/doi.org\/10.1177\/1060028020975111 (2021).","journal-title":"Ann. Pharmacother."},{"key":"40389_CR20","doi-asserted-by":"publisher","first-page":"9427","DOI":"10.21037\/apm-21-1683","volume":"10","author":"Z Xu","year":"2021","unstructured":"Xu, Z., Li, X., Li, X., Gao, Y. & Mi, X. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus. Ann. Palliat. Med. 10, 9427\u20139434. https:\/\/doi.org\/10.21037\/apm-21-1683 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"40389_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00380-021-01921-z","volume":"37","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Rivaroxaban versus vitamin K antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction. Heart Vessels 37, 374\u2013384. https:\/\/doi.org\/10.1007\/s00380-021-01921-z (2022).","journal-title":"Heart Vessels"},{"key":"40389_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40256-022-00533-w","volume":"22","author":"J Herald","year":"2022","unstructured":"Herald, J., Goitia, J., Duan, L., Chen, A. & Lee, M. Safety and effectiveness of direct oral anticoagulants versus warfarin for treating left ventricular thrombus. Am. J. Cardiovasc. Drugs 22, 437\u2013444. https:\/\/doi.org\/10.1007\/s40256-022-00533-w (2022).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"40389_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/bmjoq-2022-002111","volume":"12","author":"N Rahunathan","year":"2023","unstructured":"Rahunathan, N. et al. Improving the management of left ventricular thrombus in a tertiary cardiology centre: A quality improvement project. BMJ Open Qual. 12, 25. https:\/\/doi.org\/10.1136\/bmjoq-2022-002111 (2023).","journal-title":"BMJ Open Qual."},{"key":"40389_CR24","doi-asserted-by":"publisher","first-page":"1008031","DOI":"10.3389\/fphar.2022.1008031","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Rivaroxaban in heart failure patients with left ventricular thrombus: A retrospective study. Front. Pharmacol. 13, 1008031. https:\/\/doi.org\/10.3389\/fphar.2022.1008031 (2022).","journal-title":"Front. Pharmacol."},{"key":"40389_CR25","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1002\/ehf2.14084","volume":"9","author":"L Huang","year":"2022","unstructured":"Huang, L., Tan, Y. & Pan, Y. Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus. ESC Heart Fail. 9, 3519\u20133532. https:\/\/doi.org\/10.1002\/ehf2.14084 (2022).","journal-title":"ESC Heart Fail."},{"key":"40389_CR26","doi-asserted-by":"publisher","first-page":"e0255280","DOI":"10.1371\/journal.pone.0255280","volume":"16","author":"T Kitano","year":"2021","unstructured":"Kitano, T., Nabeshima, Y., Kataoka, M. & Takeuchi, M. Therapeutic efficacy of direct oral anticoagulants and vitamin K antagonists for left ventricular thrombus: Systematic review and meta-analysis. PLoS\u00a0One 16, e0255280. https:\/\/doi.org\/10.1371\/journal.pone.0255280 (2021).","journal-title":"PLoS\u00a0One"},{"key":"40389_CR27","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2307243","author":"Y Liang","year":"2022","unstructured":"Liang, Y., Quan, X., He, L. & Yang, Q. A meta-analysis comparing different oral anticoagulation for the treatment of ventricular thrombus. Rev. Cardiovasc. Med. https:\/\/doi.org\/10.31083\/j.rcm2307243 (2022).","journal-title":"Rev. Cardiovasc. Med."},{"key":"40389_CR28","doi-asserted-by":"publisher","first-page":"636491","DOI":"10.3389\/fcvm.2021.636491","volume":"8","author":"H Xuan","year":"2021","unstructured":"Xuan, H. et al. Safety and efficacy of vitamin K antagonists vs novel oral anticoagulants in patients with left ventricular thrombus: A meta-analysis. Front. Cardiovasc. Med. 8, 636491. https:\/\/doi.org\/10.3389\/fcvm.2021.636491 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"40389_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.repc.2021.11.013","volume":"42","author":"H da Silva Ferreira","year":"2023","unstructured":"da Silva Ferreira, H. et al. Effect of direct oral anticoagulants versus vitamin K antagonists or warfarin in patients with left ventricular thrombus outcomes: A systematic review and meta-analysis. Rev. Port Cardiol. 42, 63\u201370. https:\/\/doi.org\/10.1016\/j.repc.2021.11.013 (2023).","journal-title":"Rev. Port Cardiol."},{"key":"40389_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2021.04.007","author":"F Michael","year":"2021","unstructured":"Michael, F., Natt, N. & Shurrab, M. Direct oral anticoagulants versus vitamin K antagonists in left ventricular thrombi: A systematic review and meta-analysis. CJC Open https:\/\/doi.org\/10.1016\/j.cjco.2021.04.007 (2021).","journal-title":"CJC Open"},{"key":"40389_CR31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.amjcard.2021.03.032","volume":"150","author":"Y Saleh","year":"2021","unstructured":"Saleh, Y., Al-Abcha, A., Abdelkarim, O., Abdelnabi, M. & Almaghraby, A. Meta-analysis investigating the role of direct oral anticoagulants versus vitamin K antagonists in the treatment of left ventricular thrombi. Am. J. Cardiol. 150, 126\u2013128. https:\/\/doi.org\/10.1016\/j.amjcard.2021.03.032 (2021).","journal-title":"Am. J. Cardiol."},{"key":"40389_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1074248420977567","volume":"26","author":"C Saleiro","year":"2021","unstructured":"Saleiro, C. et al. Left ventricular thrombus therapy with direct oral anticoagulants versus vitamin K antagonists: A systematic review and meta-analysis. J. Cardiovasc. Pharmacol. Ther. 26, 233\u2013243. https:\/\/doi.org\/10.1177\/1074248420977567 (2021).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"40389_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/jce.15016","volume":"32","author":"S Shah","year":"2021","unstructured":"Shah, S. et al. Direct oral anticoagulants to treat left ventricular thrombus\u2014a systematic review and meta-analysis: ELECTRAM investigators. J. Cardiovasc. Electrophysiol. 32, 1764\u20131771. https:\/\/doi.org\/10.1111\/jce.15016 (2021).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"40389_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00015385.2020.1858538","volume":"20","author":"A Trongtorsak","year":"2021","unstructured":"Trongtorsak, A. et al. Direct oral anticoagulants vs vitamin K antagonists for left ventricular thrombus: A systematic review and meta-analysis. Acta Cardiol. 20, 1\u201310. https:\/\/doi.org\/10.1080\/00015385.2020.1858538 (2021).","journal-title":"Acta Cardiol."},{"key":"40389_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jtcvs.2020.06.063","volume":"162","author":"J Chan","year":"2021","unstructured":"Chan, J. & Harky, A. Trial sequential analysis in meta-analyses: A clinically oriented approach with real-world example. J. Thorac. Cardiovasc. Surg. 162, 167\u2013173. https:\/\/doi.org\/10.1016\/j.jtcvs.2020.06.063 (2021).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"40389_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev, J., Jakobsen, J. & Gluud, C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med. Res. Methodol. 17, 39. https:\/\/doi.org\/10.1186\/s12874-017-0315-7 (2017).","journal-title":"BMC Med. Res. Methodol."},{"key":"40389_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12874-020-01169-7","volume":"20","author":"R Claire","year":"2020","unstructured":"Claire, R., Gluud, C., Berlin, I., Coleman, T. & Leonardi-Bee, J. Using trial sequential analysis for estimating the sample sizes of further trials: Example using smoking cessation intervention. BMC Med. Res. Methodol. 20, 284. https:\/\/doi.org\/10.1186\/s12874-020-01169-7 (2020).","journal-title":"BMC Med. Res. Methodol."},{"key":"40389_CR38","unstructured":"Thorlund, K. et al. User manual for trial sequential analysis (TSA). (2017)."},{"key":"40389_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z (2010).","journal-title":"Eur. J. Epidemiol."},{"key":"40389_CR40","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"J Sterne","year":"2019","unstructured":"Sterne, J. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898. https:\/\/doi.org\/10.1136\/bmj.l4898 (2019).","journal-title":"BMJ"},{"key":"40389_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/TCRM.S84210","volume":"11","author":"Y Mekaj","year":"2015","unstructured":"Mekaj, Y., Mekaj, A., Duci, S. & Miftari, E. New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther. Clin. Risk Manage. 11, 967\u2013977. https:\/\/doi.org\/10.2147\/TCRM.S84210 (2015).","journal-title":"Ther. Clin. Risk Manage."},{"key":"40389_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"G Raskob","year":"2018","unstructured":"Raskob, G. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 378, 615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948 (2018).","journal-title":"N. Engl. J. Med."},{"key":"40389_CR43","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"H Guimaraes","year":"2020","unstructured":"Guimaraes, H. et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N. Engl. J. Med. 383, 2117\u20132126. https:\/\/doi.org\/10.1056\/NEJMoa2029603 (2020).","journal-title":"N. Engl. J. Med."},{"key":"40389_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"J Brok","year":"2008","unstructured":"Brok, J., Thorlund, K., Gluud, C. & Wetterslev, J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J. Clin. Epidemiol. 61, 763\u2013769. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.10.007 (2008).","journal-title":"J. Clin. Epidemiol."},{"key":"40389_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","volume":"38","author":"J Brok","year":"2009","unstructured":"Brok, J., Thorlund, K., Wetterslev, J. & Gluud, C. Apparently conclusive meta-analyses may be inconclusive-trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int. J. Epidemiol. 38, 287\u2013298. https:\/\/doi.org\/10.1093\/ije\/dyn188 (2009).","journal-title":"Int. J. Epidemiol."},{"key":"40389_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jclinepi.2018.10.009","volume":"106","author":"G Gartlehner","year":"2019","unstructured":"Gartlehner, G. et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. J. Clin. Epidemiol. 106, 50\u201359. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.10.009 (2019).","journal-title":"J. Clin. Epidemiol."},{"key":"40389_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","volume":"38","author":"K Thorlund","year":"2009","unstructured":"Thorlund, K. et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int. J. Epidemiol. 38, 276\u2013286. https:\/\/doi.org\/10.1093\/ije\/dyn179 (2009).","journal-title":"Int. J. Epidemiol."},{"key":"40389_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev, J., Thorlund, K., Brok, J. & Gluud, C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J. Clin. Epidemiol. 61, 64\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.013 (2008).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40389-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:04:26Z","timestamp":1700381066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40389-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40389"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-40389-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"17 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13203"}}